Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 7/20 | 0.48 |
| ▸ | CA2 | P00918 | 7/20 | 0.48 |
| ▸ | CA9 | Q16790 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CA4 | P22748 | 2/20 | 0.47 |
| ▸ | CA7 | P43166 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6626661 | 0.90 | PTGS2 (0.46) | PTGS2CA1CA2CA9CA4 | |
| SCHEMBL6342809 | 0.89 | PTGS2 (0.49) | PTGS2CA1CA2CA9CA4 | |
| SCHEMBL6343697 | 0.87 | PTGS2 (0.46) | PTGS2CA1CA2CA9KMT2A | |
| SCHEMBL6340626 | 0.87 | KMT2A (0.55) | PTGS2CA1CA2CA9POLB | |
| SCHEMBL6354562 | 0.85 | PTGS2 (0.46) | PTGS2CA1CA2CA9CA4 | |
| SCHEMBL6343380 | 0.84 | PTGS2 (0.49) | PTGS2CA1CA2CA9POLB | |
| SCHEMBL6350930 | 0.84 | KMT2A (0.46) | PTGS2CA1CA2CA9POLB | |
| SCHEMBL6342695 | 0.83 | IKBKB (0.51) | PTGS2MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL6342102 | 0.83 | CA2 (0.48) | PTGS2CA1CA2CA9CA4 | |
| SCHEMBL6353442 | 0.82 | CRACR2A (0.43) | PTGS2KMT2AMAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030125361-A1 | Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation | PHARMACIA CORPORATION | 2003-07-03 | — | — | US | claimed |
| US-6849653-B2 | 1H-benzo(g)indazole compounds as anticarcinogenic agents and also treat arthritis | PHARMACIA CORPORATION (US) | 2005-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125361-A1 | Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation | IRAK4, NLRP3, CXCL8 | PTGS2 37/4885CA1 3893/4885CA2 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.